



AF/1623

PATENT

Customer No. 22,852

Attorney Docket No. 7579.0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)
)
Graham Edmund KELLY) Group Art Unit: 1623
)
Reissue Serial No.: 09/602,191) Examiner: Patrick T. LEWIS
)
U.S. Patent No. 5,830,887)
)
Filed: June 22, 2000)
)
For: HEALTH SUPPLEMENTS CONTAINING)
PHYTO-OESTROGENS, ANALOGUES)
OR METABOLITES THEREOF)

MAIL STOP AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(d)

Pursuant to 37 C.F.R. § 1.56, Applicant brings to the attention of the Examiner the documents listed on the attached Form PTO 1449. This Information Disclosure Statement is being filed after the mailing date of a Final Action. Applicant respectfully requests that the Examiner waive the rule and kindly consider this Information Disclosure Statement because of the Examiner's familiarity with this case and its related co-pending cases. If the Examiner declines to consider these references, Applicant respectfully requests that these papers be placed in the file pursuant to 37 C.F.R. § 1.97(i). Should the Examiner kindly consider this Information Disclosure Statement, Applicant authorizes the Office to deduct the fee of \$180.00 as specified by 37 C.F.R. § 1.17(p) from our Deposit Account No. 06-0916.

Applicant also wishes to direct the Office's attention to Interference Proceeding No. 104,576 involving the Gorbach U.S. Patent No. 5,498,631 ("the '631"). In that interference, Stanley Gorbach was the senior party. The junior party, Graham Edmund Kelly, one of the

inventors in this application, successfully argued the priority of U.S. Application Serial No. 08/910,837. Thus, to the extent that the presently pending claims are similar to the Kelly claims in interference, the '631 Gorbach patent is not a proper reference under Section 102.

Finally, Applicant also submits the following declarations obtained from opposition proceedings on patents related to this patent application in Australia and New Zealand. The following documents from these proceedings were previously submitted to the USPTO in possibly related applications. In the Information Disclosure Statement filed on June 22, 2000, for this application Applicant submitted these documents but did not include them on Form PTO 1449. Applicant now includes them on the attached Form PTO 1449.

1. Statutory Declaration of Fiona Bathgate.
2. Statutory Declaration of Nancy Beckham.
3. Statutory Declaration of Kerry Martin Bone.
4. Statutory Declaration of Jennifer Carpinelli.
5. Statutory Declaration of G. Clements.
6. Statutory Declaration of Julie Hill.
7. Statutory Declaration of Norbert Krause.
8. Statutory Declaration of Ngaire Petit-Young.
9. Statutory Declaration of Hubert Regtop.
10. Statutory Declaration of Joseph Nicolas Van Haaster.

Copies of the listed documents are attached. German published application DE 44 32 947 A1 is not in English. In lieu of a statement of relevance or translation of the non-English documents, English language versions of the Supplementary Partial European Search Report dated October 11, 2002, citing this document and setting forth its relevance is enclosed. Schultz, in German, and Deschamps-Vallet, in French, have certified English translations attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 9, 2004

By: 
Robert W. Mann
Reg. No. 48,555

**INFORMATION DISCLOSURE CITATION**


OMB No. 0651-0011

Atty. Docket No.	07579-0001-00000	Serial No.	09/602,191
Applicant	Graham Edmund KELLY		
Filing Date	June 22, 2000	Group:	1623

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	2002 0035074-A1		Kelly			03/21/2002
	3,471,520	10/07/1969	Irmscher et al.			
	3,535,344	10/20/1970	Irmscher et al.			
	4,157,984	06/12/1979	Zilliken			
	4,428,876	01/31/1984	Iwamura			
	4,814,346	03/21/1989	Albert et al.			
	5,153,230	10/06/1992	Jafery			
	5,247,102	09/21/1993	Kállay et al.			
	5,523,087	06/04/1996	Shlyankevich			
	5,639,785	06/17/1997	Kung			
	5,702,752	12/30/1997	Gugger et al.			
	5,733,926	03/31/1998	Gorbach			
	5,804,234	09/08/1998	Suh et al.			
	5,855,892	1/5/1999	Potter et al.			
	5,942,539	08/24/99	Hughes, Jr. et al.			
	6,060,070	05/09/2000	Gorbach			
	6,235,773	05/22/2001	Bissett			
	6,599,536	07/29/2003	Kelly et al.			
	6,642,212	11/04/2003	Kelly			
	6,649,648	11/18/2003	Kelly et al.			


Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION


Atty. Docket No.	07579-0001-00000	Serial No.	09/602,191
Applicant	Graham Edmund KELLY		
Filing Date	June 22, 2000	Group:	1623



FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	AU-A-10227/95	07/27/1995	Australia			
	AU-A-27714/00	11/23/2000	Australia			
	AU-A-73072/98	09/30/1999	Australia			
	AU-B-80655/87	05/05/1988	Australia			
	DE 44 32 947 A1	03/21/1996	Germany			No
	EP 0 671 170 A1	09/13/1995	Europe			
	EP 0 795 553 A1	09/17/1997	Europe			
	EP 0 906 761 A2	04/07/1999	Europe			
	GB 1 495 189 A	12/14/1977	Great Britain			
	JP S50-0035393	04/04/1975	Japan			Abstract
	JP S50-101360 A	08/11/1975	Japan			Abstract
	JP S50-160483 A	12/25/1975	Japan			Abstract
	JP S61-247396 A	04/11/1986	Japan			Abstract
	JP S62-106017 A	05/16/1987	Japan			Abstract
	JP H01-042427 A	02/14/1989	Japan			Abstract
	JP H01-226824 A	09/11/1989	Japan			Abstract
	JP H02-124883 A	05/14/1990	Japan			Abstract
	JP H05-170756 A	07/09/1993	Japan			Abstract
	JP H06-040876 A	02/15/1994	Japan			Abstract
	JP H06-040909 A	02/15/1994	Japan			Abstract
	JP H06-086682 A	03/29/1994	Japan			Abstract
	JP H06-321752 A	11/22/1994	Japan			Abstract

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



OMB No. 0651-0011


INFORMATION DISCLOSURE CITATION

Atty. Docket No. 07579-0001-00000	Serial No. 09/602,191
Applicant Graham Edmund KELLY	
Filing Date June 22, 2000	Group: 1623

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	JP H07-173148 A	07/11/1995	Japan			Abstract
	JP H09-067362 A	03/11/1997	Japan			Abstract
	JP H10-059956 A	03/03/1998	Japan			Abstract
	WO 91/14429 A1	10/03/1991	PCT			
	WO 95/03293 A1	02/02/1995	PCT			
	WO 96/10341 A1	04/11/1996	PCT			
	WO 97/06273 A1	02/20/1997	PCT			
	WO 98/08503 A1	03/05/1998	PCT			
	WO 98/48790 A1	11/05/1998	PCT			
	WO 98/49153 A1	11/05/1998	PCT			
	WO 98/52546 A1	11/26/1998	PCT			
	WO 98/56373	12/17/1998	PCT			
	WO 99/11260 A1	03/11/1999	PCT			
	WO 99/11263 A1	03/11/1999	PCT			
	WO 99/18927 A1	04/22/1999	PCT			Abstract
	WO 99/36050 A1	07/22/1999	PCT			
	WO 99/37633 A1	07/29/1999	PCT			Abstract
	WO 99/43335 A1	09/02/1999	PCT			
	WO 00/03707 A1	01/27/2000	PCT			Abstract
	WO 00/16759 A2	03/30/2000	PCT			
	WO 00/54753 A2	09/21/2000	PCT			
	WO 00/62765 A2	10/ 26/2000	PCT			

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
<p>Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce</p>	



INFORMATION DISCLOSURE CITATION

Atty. Patrick N. Kelly	07579-0001-00000	Serial No.	09/602,191
Applicant		Graham Edmund KELLY	
Filing Date	June 22, 2000	Group:	1623


FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	WO 00/64438 A1	11/02/2000	PCT			
	WO 00/66576 A1	11/09/2000	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Adlercreutz, H. et al., "Effect of Dietary Components, Including Lignans and Phytoestrogens, on Enterohepatic Circulation and Liver Metabolism of Estrogens and on Sex Hormone Binding Globulin (SHBG)," <i>J. steroid Biochem</i> , Vol. 27, No. 4-6, pp. 1135-1144 (1987).
	Akkad, Andrea A. et al., "Abnormal Uterine Bleeding on Hormone Replacement: The Importance of Intrauterine Structural Abnormalities," <i>Obstetrics & Gynecology</i> , Vol. 86, pp. 330-334 (1995).
	Alegrio, L.V. et al.; "Diarylheptanoids and Isoflavonoids from <i>Centrolobium</i> Species"; <i>Phytochemistry</i> , Vol. 28, No. 9, pp. 2359-2362, (1989).
	Al-Maharik, N.I. et al., "Synthesis of C-C-Bridged Bis-Isoflavones," <i>J. Org. Chem.</i> , Vol. 65, pp. 2305-2308, (2000).
	Anderson et al. "Biphasic Effects of Genistein on Bone Tissue in the Ovariectomized, Lactating Rat Model," <i>P.S. E. B. M.</i> Vol. 217, pp. 345-350, (1998).
	Baber, R. et al. "The effect of an isoflavone dietary supplement (Rismostil) on serum lipids, forearm bone density and endometrial thickness in post-menopausal women," <i>Proc 10th Annual Meeting of the North American Menopause Society</i> , New York, 23-25 September 1999
	Bannerjee et al., "Polarography of Flavanone and Isoflavone", <i>J. Electrochem. Soc. India</i> , Vol. 47, No. 4, pp. 237-244, (October 1998).
	Bannwart, C. et al., "Identification of the isoflavonic phytoestrogen daidzein in human urine," <i>Clinica Chimica Acta</i> , Vol. 136, Nos. 2-3, pp. 165-172, (January 1984).
	Beylot "Clinical signs of skin ageing." <i>Revue Francaise de Gynecologie et d'Obstetrique</i> , (1991) 86/6 (433-441) ISSN: 0035-290X.
	Bezuidenhoudt, B.C.B. et al., "Synthesis of Isoflavanoid Oligomers Using a Pterocarpan as Inceptive Electrophile," <i>J. Chem. Soc. Perkin Transactions I</i> , pp. 2767-2778.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce




OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	07579-0001-00000	Serial No.	09/602,191
Applicant	Graham Edmund KELLY		
Filing Date	June 22, 2000	Group:	1623

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Bingham, S.A. et al., "Phyto-oestrogens: where are we now?," British Journal of Nutrition, Vol. 79, pp. 393-406.
	Burali, C. et al., "Synthesis and Anti-Rhinovirus Activity of Halogen-Substituted Isoflavenes and Isoflavans," <i>European Journal of Medicinal Chemistry</i> , Editions Scientifique Elsevier, Paris, FR, 22(2):119-123 (April 1987).
	Cassady, J.M. et al., "Use of a Mammalian Cell Culture Benzo(a)pyrene Metabolism Assay for the Detection of Potential Anticarcinogens from Natural Products: Inhibition of Metabolism by Biochanin A, an Isoflavone from <i>Trifolium pratense</i> L, Cancer Research, Vol. 48 (22), pp. 6257-6261, (November 1998).
	Caswell, A. (ed) "Hypolipidaemic Agent," MIMS Annual, 23 rd edition, pp. 2-152 to 2-169, Singapore (1999).
	Chan, K. et al., "Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women," <i>Lancet</i> ; 355(9222):2185-8, June 24, 2000.
	Chang et al., "Metabolites of daidzein and genistein and their biological activities." <i>Journal of Natural Products</i> (1995), 58(12), pp. 1901-5, ISSN: 0163-3864.
	Chang Y., "Microwave-Mediated Synthesis of Anticarcinogenic Isoflavones from Soybeans," <i>J Agric Food Chem</i> . 1994, 42: 1869-1871
	Chicago Center for Clinical Research, Company Press Release March 13, 2000, "Chicago Center for Clinical Research Study suggests New, More Effective Way to Treat Older Women with High Cholesterol"
	Clifton-Bligh, P. et al., "The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism," <i>Menopause</i> (in submission), pp. 1-27, 2000.
	Collins, B.M. et al., "The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast," <i>Steroids</i> , Vol. 62, pp. 365-372, (April 1997).
	Deschamps-Vallet, C. et al., "Transformation Du Cation Isoflavylum en Phenyl-3 Coumarines, Isoflavenes-3 et Isoflavannes," <i>Tetrahedron Letters</i> , 24(37):3993-3996 (1983).
	Doren, M. et al., "Identification and Treatment of Postmenopausal Women at Risk for the Development of Osteoporosis," <i>International Journal of Clinical Pharmacology, Therapy and Toxicology</i> , Vol. 20, No. 11, pp. 431-433 (1992).
	Dubey et al. "Phytoestrogens Inhibit Growth and MAP Kinase Activity in Human Aortic Smooth Muscle Cells," <i>Hypertension</i> , Vol. 33 (part II), pp. 177-182, (1999).
	Ellis, G.P. (ed.); "Chromenes, Chromanones, and Chromones"; pages 256-260; published by John Wiley & Sons, 1977.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce




INFORMATION DISCLOSURE CITATION

Attorney Docket No.	07579-0001-00000	Serial No.	09/602,191
Applicant		Graham Edmund KELLY	
Filing Date	June 22, 2000	Group:	1623

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Evans, D. et al., "Ovarian Cancer Family and Prophylactic Choices," <i>Journal of Medical Genetics</i> , pp. 416-418, 1991.
	Evans, M. et al., "Hormone Replacement Therapy: Management of Common Problems," <i>Mayo Clin. Proc.</i> , Vol. 70, pp. 800-805, (1995).
	Fanti et al. "The Phytoestrogen Genistein Reduces Bone Loss in Short-Term Ovariectomized Rats," <i>Osteoporosis Int.</i> , Vol. 8, pp. 274-281, (1998).
	Goh, J.T.W. et al., "Postmenopausal Endometrioma and Hormonal Replacement Therapy," <i>Aust NZ J. Obstet Gynaecol</i> , Vol. 32, pp. 384-385 (1992).
	Graham, T. L., "Flavonoid and Isoflavonoid Distribution in Developing Soybean Seedling Tissues and in Seed and Root Exudates," <i>Pharm. Physiol.</i> Vol. 95, pp. 594-603, (1991).
	Grodstein, F., et al., "Postmenopausal Hormone Use and Cholecystectomy in a Large Prospective Study," <i>Obstetrics & Gynecology</i> , Vol. 83, No.1, pp. 5-11 (1994).
	Hebert, P. et al., (1997), "Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials," <i>JAMA</i> 278(4):313-21
	Hodgson, J. et al., (1998), "Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomised controlled trial in humans," <i>Journal of Nutrition</i> , 128: 728-332.
	Hulley, S. et al., (1998), "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women," <i>JAMA</i> 280(7): 605-613.
	Inoue, N., 1964, "Studies of Synthetic Isoflavones. V. The Reduction of Isoflavone," originally from <i>Bull. Chem. Soc. Japan</i> , May 1964, 37(5): 601-605, cited in <i>STN International, CAPLUS database</i> , (Columbus, Ohio), No. 61: 32297 (2 pages).
	Jurd, L. et al.; "Phenolic and Quinoidal Constituents of <i>Dalbergia Retusa</i> ," <i>Tetrahedron Letters</i> , Vol. 21, pages 2149-2152; (1972).
	Kao, Y., et al., "Molecular Basis of the Inhibition of Human Aromatase (Estrogen Synthetase) by Flavone and Isoflavone Phytoestrogens: A Site-directed Mutagenesis Study," <i>Environmental Health Perspectives</i> , Vol. 106, No. 2, pp. 85-92 (1998).
	Kelly et al., "Metabolites of dietary (soya) isoflavones in human urine," <i>Clinica Chimica Acta</i> 223(1-2), pp. 9-22 (December 31,1993).
	KELLY, S. A. et al., "Protein Tyrosine Phosphorylation Mediates TNF-Induced Endothelial-Neutrophil Adhesion in Vitro", <i>The American Physiological Society</i> , 274 (2Pt2), pp. H513-H519, (1998).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce




INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

Atty. Docket No.	07579-0001-00000	Serial No.	09/602,191
Applicant	Graham Edmund KELLY		
Filing Date	June 22, 2000	Group:	1623

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Lamberton, et al., "Catalytic Hydrogenation of Isoflavones. the Preparation of (±)-Equol and Related Isoflavans", Aust. J. Chem. Vol. 31, pp. 455-457, (February 1978).
	Liepa, A.J. "A Synthesis of Hydroxylated Isoflavylum Salts and Their Reduction Products", Aust. J. Chem., Vol. 34, pp. 2647-2655, (1981).
	Lindner, H.R., "V/1 Occurrence of Anabolic Agents in Plants and their Importance," Environmental Quality and Safety Supplement, Thieme, Stuttgart, Germany, 1976, 5: 151-158.
	Liu, Y. et al., "Abstract No. 78763p; Effects of solid dispersion of diadzein on the blood pressure of spontaneously hypersensitive rats," Chemical Abstracts, Vol. 115, No. 8, p. 466 (Aug. 26, 1991).
	Mäkelä, S., et al., "Inhibition of 17β-Hydroxysteroid Oxidoreductase by Flavonoids in Breast and Prostate Cancer Cells," pp. 310-316 (1998).
	MAY, M. J. et al., "Effects of Protein Tyrosine Kinase Inhibitors on Cytokine-Induced Adhesion Molecule Expression by Human Umbilical Vein Endothelial Cells", British Journal of Pharmacology, No. 118, pp. 1761-1771, (1996).
	Mazur et al.; "Natural and anthropogenic environmental oestrogens: the scientific basis for risk assessment* -Naturally occurring oestrogens in food," Pure & Appl. Chem. 70(9), pp. 1759-1776 (1998).
	Namnoum, A.B., et al., "Incidence of symptom recurrence after hysterectomy for endometriosis," <i>Fertility and Sterility</i> , Vol. 64, No. 5, pp. 898-902 (1995).
	Nestel, P. et al., (1997), "Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and peri-menopausal women," <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> 17: 3392-3398
	Nestel, P. et al., (1999), "Isoflavones from red clover improves systemic arterial compliance but not plasma lipids in menopausal women," <i>Journal of Clinical Endocrinology and Metabolism</i> 84: 895-898
	PALMETSHOFER, A. et al., "α-Galactosyl Epitope-Mediated Activation of Porcine Aortic Endothelial Cells", <i>Transplantation</i> , Vol. 65, No. 7, pp. 971-978, (April 15, 1998).
	Panchagnula, R. et al., "Transdermal iontophoresis revisited," <i>Curr. Opin. Chem. Biol</i> , 2000 Aug; 4(4):468-73
	Parfitt, K., Martindale 32 nd edition, "The complete drug reference," (1999), 32 nd Edition,. Pharmaceutical Press, London, pp. v. and vi.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce




OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	07579-0001-00000	Serial No.	09/602,191
Applicant	Graham Edmund KELLY		
Filing Date	June 22, 2000	Group:	1623

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Peterson, G. et al., "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," <i>The Prostate</i> , Vol. 22, No. 4, pp. 335-345, (1993).
	Peterson, G. et al., "Genistein Inhibition of the Growth of Human Breast Cancer Cells: Independence From Estrogen Receptors and the Multi-drug Resistance Gene," <i>Biochemical and Biophysical Research Communications</i> , Vol. 179, No. 1, pp. 661-667, (August 1991).
	Potter, S. et al., (1998), "Soy protein and isoflavones: their effect on blood lipids and bone density in postmenopausal women," <i>American Journal of Clinical Nutrition</i> , 68(Suppl):1375S-1379S.
	Sacks, F. et al., (1996), "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels," <i>Cholesterol and Recurrent Events Trial Investigators</i> , <i>New England Journal of Medicine</i> , 335(14):1001-9
	Samman, S. et al., (1999), "The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in pre-menopausal women," <i>Atherosclerosis</i> 147:277-283.
	Sanchez-Guerrero, J. et al., "Postmenopausal Estrogen Therapy and the Risk for Developing Systemic Lupus Erythematosus," <i>Annals of Internal Medicine</i> , Vol. 122, No. 6, pp. 430-433 (1995).
	Sbarouni, E. et al., (1998), "The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease," <i>Journal of the American College of Cardiology</i> 32(5): 122-50.
	Scandinavian Simvastatin Survival Study Group, (1994), "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinav Simvastatin Survivl Study (4S)," <i>Lancet</i> 344:1383-89
	Schultz, "Isoflavonglucoside Formononetin-7-glucosid und Biochanin A-7-glucosid in <i>Trifolium pratense</i> L.," <i>Die Naturwissenschaften</i> , 52(18), p. 517, Sept. 1965.
	Sener, A.B., et al., "The effects of hormone replacement therapy on uterine fibroids in postmenopausal women," <i>Fertility and Sterility</i> , Vol. 65, No. 2, pp. 354-357 (1996).
	Siddiqui et al. "Hypolipidemic principles of <i>Cicer Arietinum</i> : Biochanin-A and Formononetin," <i>Lipids</i> , Vol. 11, No. 3, pp. 243-246, (1975)
	Stampfer, M. et al., "A Prospective Study of Cholesterol, Apolipoproteins, and the Risk of Myocardial Infarction," <i>The New England Journal of Medicine</i> , Vol. 325, No. 6, pp. 373-381, (1991)
	Statutory Declaration of Fiona Bathgate, declared March 24, 1998, 4 pages.
	Amended Statutory Declaration of Fiona Bathgate, declared October 26, 1998, 2 pages.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION

Applicant No.	07579-0001-00000	Serial No.	09/602,191
Applicant	Graham Edmund KELLY		
Filing Date	June 22, 2000	Group:	1623

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Statutory Declaration of Nancy Beckham, declared September 8, 1998, 20 pages.
	Statutory Declaration of Kerry Martin Bone, declared October 5, 1998, 31 pages.
	Statutory Declaration of Jennifer Carpinelli, declared October 21, 1998, 2 pages.
	Statutory Declaration of G. Clements, declared January 27, 1999, 2 pages.
	Statutory Declaration of Julie Hill, declared April 4, 1998, 2 pages.
	Statutory Declaration of Norbert Krause, declared November 5, 1998, 23 pages.
	Statutory Declaration of Ngairé Petit-Young, declared November 5, 1998, 3 pages.
	Statutory Declaration of Hubert Regtop, declared November 24, 1998, 53 pages.
	Statutory Declaration of Joseph Nicolas Van Haaster, declared January 26, 1999, including Exhibit "JNVH-1," 20 pages.
	Supplemental Partial European Search Report issued for Application No. EP 99 91 2976
	Szabo et al., 1973, "The Selective Reduction of Isoflavon," <i>Tetrahedron Letters</i> , 19: 1659-1662.
	Troisi, R.J., et al., "Menopause, Postmenopausal Estrogen Preparations and the Risk of Adult-Onset Asthma," <i>Am J Respir Crit Care Med</i> , Vol. 152, pp. 1183-1188 (1995).
	Wähälä, K. et al., "Hydrogen Transfer Reduction of Isoflavones," <i>Heterocycles</i> , 28(1):183-186 (1989).
	Wang, C., et al., "Phytoestrogen Concentration Determines Effects on DNA Synthesis in Human Breast Cancer Cells," <i>Nutrition and Cancer</i> , 28(3), pp. 236-247, (1997).
	WEBER, C., "Involvement of Tyrosine Phosphorylation in Endothelial Adhesion Molecule Induction", <i>Immunologic Research</i> , No. 15, pp. 30-37, (1996).
	Welshons, W.V. et al., "Stimulation of breast cancer cells <i>in vitro</i> by the environmental estrogen enterolactin and the phytoestrogen equol," <i>Breast Cancer Research and Treatment</i> , Vol. 10, 169-175, (1987).
	Whalley, W.B., "5:4'-Dihydroxy-8-Methylisoflavone, and a Note on Lotoflavin," <i>Journal of the Chemical Society</i> , pp. 1833-1837, (1957).
	Winship, K.A., "Unopposed estrogens," <i>Adv. Drug React. Ac. Pois. Rev.</i> , Vol. 1, pp. 37-66, (1987).
	Yahara, S. et al., "Isoflavan and Related Compounds from <i>Dalbergia odorifera</i> . I" <i>Chem, Pharm. Bull.</i> 37(4): 979-987 (April 1989).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce